Casper Pharma
As of the edition of 20 October 2026, Casper Pharma runs 12 drugs, 12 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 12 |
| Total | 12 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Glycopyrronium | none listed | 10 |
| Allopurinol | none listed | 0 |
| Azathioprine | none listed | 2 |
| Chlorthalidone | none listed | 1 |
| Retinol | none listed | 0 |
| Fludrocortisone | none listed | 0 |
| Penicillin g | none listed | 0 |
| Nitrofurantoin | none listed | 0 |
| Fludrocortisone acetate | none listed | 1 |
| Meclizine | none listed | 1 |
| Vitamin a palmitate | none listed | 0 |
| Tiopronin | Ended 2026 (exclusivity) | 0 |
A route B row is one company at one target.